ClinicalTrials.gg
Active, not recruitingNCT03170960Updated Oct 1, 2026

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of cabozantinib and atezolizumab in Urothelial Carcinoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer, sponsored by Exelixis. Active, not recruiting at 124 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
914
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing atezolizumab in Carcinoma, Transitional Cell — 1 open to participants now, 4 under way, 1 of them phase 3. atezolizumab · Carcinoma, Transitional Cell.

Enrollment
2nd of 15
914 · median 32
Started
2017
with 2 others
Phase 1
Only one
of the 15
Registered
7th of 15
by date
Lead sponsor
1 of 15
Exelixis

Among the 15 studies testing atezolizumab in Carcinoma, Transitional Cell, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is the only one in phase 1, and was the 7th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

1 of the 15 studies testing atezolizumab in Carcinoma, Transitional Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing atezolizumab in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.

Read the detailed description
  • Dose Escalation Stage: to determine the schedule and maximum tolerated dose (MTD) and/or recommended Expansion Stage dose of cabozantinib when taken in combination with a standard dosing regimen of atezolizumab (1200 mg infusion, once every 3 weeks).
  • Expansion Stage: to determine the preliminary efficacy (objective response rate [ORR] per RECIST 1.1) and safety of the recommended combination dose of cabozantinib with atezolizumab in eighteen tumor-specific cohorts including subjects with advanced UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC/LEC, CRC, H\&N, and DTC.
  • Exploratory SAC Cohorts: Descriptive efficacy, safety, PK, and biomarker analyses of single-agent cabozantinib in UC, NSCLC, and CRPC subjects. Descriptive efficacy and safety analyses of combination therapy after progression on single-agent therapy
  • Exploratory SAA Cohort: Descriptive efficacy, safety, PK, and biomarker analyses of single-agent atezolizumab in CRPC subjects. Descriptive efficacy and safety analyses of combination therapy after progression on single-agent therapy
03

Conditions studied

  • Urothelial Carcinoma
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer
  • Castration-resistant Prostate Cancer
  • Triple Negative Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Hepatocellular Carcinoma
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Colorectal Cancer
  • Head and Neck Cancer
  • Differentiated Thyroid Cancer
  • Lower Esophageal Cancer

Keywords

  • Kidney
  • Bladder
  • Renal pelvis
  • Ureter
  • Urethra
  • Cancer
  • Prostate
  • Castration-resistant
  • Lung
  • Breast
  • Ovarian
  • Endometrial
  • Liver
  • Stomach
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, , or recurrent:

    • Dose-Escalation Stage:

      • Subjects with UC (including renal pelvis, ureter, bladder, urethra) after prior platinum-based therapy, or
      • Subjects with RCC (clear cell, non-clear cell histology) with or without prior systemic anticancer therapy
    • Expansion Stage:

      • Inoperable locally advanced or metastatic solid tumor (UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC/LEC, CRC, H\&N cancer, and DTC as outlined above)
  2. per 1.1 as determined by the investigator.
  3. Tumor tissue material available (archival or recent tumor )
  4. Recovery to baseline or ≤ Grade 1 v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  5. Age eighteen years or older on the day of consent.
  6. (ECOG) Performance Status of 0 or 1.
  7. Adequate organ and marrow function.
  8. Sexually active fertile subjects and their partners must agree to use medically accepted methods of .
  9. Female subjects of must not be pregnant at screening.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with cabozantinib or including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5, 7, 9, 11, 17, 19 and 20. Other restrictions regarding prior therapy may apply.
  2. Known or cranial epidural disease unless adequately treated and stable for at least 4 weeks before first dose of study treatment.
  3. Concomitant anticoagulation with oral anticoagulants.
  4. Subject is receiving systemic therapy (>10 mg daily prednisone equivalent) or any other form of therapy within 2 weeks prior to first dose of study treatment.
  5. Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
  6. The subject has uncontrolled, significant intercurrent or recent illness, including, but not limited to, an active or history of disease or immune deficiency; idiopathic pulmonary fibrosis, organizing pneumonia, pneumonitis; active infection requiring systemic treatment, infection with (HIV), AIDS-related illness, acute or chronic or C infection, positive test for tuberculosis, moderate to severe hepatic impairment ( B or C).
  7. Pregnant or lactating females.
  8. Previously identified allergy or to components of the study treatment formulations.
  9. Diagnosis of another within 2 years before first dose of study treatment.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
914 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard "3 plus 3" design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage.

    Drug: cabozantinib · Drug: atezolizumab

  • Experimental
    Expansion Cohort 1

    RCC subjects with clear cell histology who have not received prior systemic anticancer therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 2

    UC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 3

    UC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 4

    UC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 5

    UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 6

    CRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 7

    Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 8

    Stage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 9

    Stage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 10

    RCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 11

    TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 12

    OC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 13

    EC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 14

    HCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 15

    GC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 16

    CRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 17

    H\&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 18

    DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 19 (SAC)

    UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.

    Drug: cabozantinib

  • Experimental
    Expansion Cohort 20 (SAC)

    Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.

    Drug: cabozantinib

  • Experimental
    Expansion Cohort 21 (SAC)

    Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.

    Drug: cabozantinib

  • Experimental
    Expansion Cohort 22 (SAA)

    Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.

    Drug: atezolizumab

  • Experimental
    Expansion Cohort 23

    Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC

    Drug: atezolizumab · Drug: cabozantinib

  • Experimental
    Expansion Cohort 24

    Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC

    Drug: atezolizumab · Drug: cabozantinib

Interventions

  • Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.

    Also known as: Cabometyx, XL184

  • Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

    Also known as: Tecentriq

  • Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

    Also known as: Cabometyx, XL184

  • Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd

    Also known as: Cabometyx, XL184

06

What researchers measure

Primary outcomes

  1. Dose Escalation: MTD/Recommended Dose

    To determine the maximum tolerated dose (MTD) and/or recommended dose and schedule for the subsequent Expansion Stage of daily oral administration of cabozantinib in subjects with solid tumors when taken in combination with atezolizumab.

    Time frame: Up to Day 21

  2. Dose Expansion: ORR

    To evaluate preliminary efficacy by estimating the Objective Response Rate (ORR) as assessed by the Investigator per RECIST 1.1.

    Time frame: Up to a maximum of 59 months

Secondary outcomes

  1. Incidence and severity of nonserious AEs and SAEs (Safety)

    To assess safety for the combination therapy through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs), including immune-related adverse events (irAEs) and adverse events of special interest (AESIs).

    Time frame: From first dose to 30 days following last dose (up to a maximum of 59 months)

07

Study locations

124 sites
  • Exelixis Clinical Site #53
    Gilbert, Arizona 85234, United States
  • Exelixis Clinical Site #18
    Phoenix, Arizona 85054, United States
  • Exelixis Clinical Site #1
    Duarte, California 91010, United States
  • Exelixis Clinical Site #20
    La Jolla, California 92090, United States
  • Exelixis Clinical Site #46
    Los Angeles, California 90025, United States
  • Exelixis Clinical Site #51
    Newport Beach, California 92663, United States
  • Exelixis Clinical Site #62
    Santa Monica, California 90404, United States
  • Exelixis Clinical Site #21
    Stanford, California 94305, United States
  • Exelixis Clinical Site #34
    Denver, Colorado 80218, United States
  • Exelixis Clinical Site #50
    Denver, Colorado 80218, United States
  • Exelixis Clinical Site #42
    New Haven, Connecticut 06511, United States
  • Exelixis Clinical Site #48
    Washington D.C., District of Columbia 20007, United States
  • Exelixis Clinical Site #16
    Jacksonville, Florida 32224, United States
  • Exelixis Clinical Site #76
    Tampa, Florida 33612, United States
  • Exelixis Clinical Site #60
    Atlanta, Georgia 30318, United States
  • Exelixis Clinical Site #79
    Atlanta, Georgia 30341, United States
  • Exelixis Clinical Site #32
    Harvey, Illinois 60426, United States
  • Exelixis Clinical Site #23
    Fairway, Kansas 66205, United States
  • Exelixis Clinical Site #57
    Lexington, Kentucky 40536, United States
  • Exelixis Clinical Site #24
    New Orleans, Louisiana 70112, United States
  • Exelixis Clinical Site #10
    Boston, Massachusetts 02215, United States
  • Exelixis Clinical Site #3
    Detroit, Michigan 48201, United States
  • Exelixis Clinical Site #17
    Rochester, Minnesota 55905, United States
  • Exelixis Clinical Site #65
    Bolivar, Missouri 65613, United States
  • Exelixis Clinical Site #43
    Kansas City, Missouri 64111, United States
  • Exelixis Clinical Site #35
    Omaha, Nebraska 68130, United States
  • Exelixis Clinical Site #59
    Omaha, Nebraska 68130, United States
  • Exelixis Clinical Site #61
    Las Vegas, Nevada 89169, United States
  • Exelixis Clinical Site #38
    Camden, New Jersey 08103, United States
  • Exelixis Clinical Site #27
    East Brunswick, New Jersey 08816, United States
  • Exelixis Clinical Site #31
    New Brunswick, New Jersey 08903, United States
  • Exelixis Clinical Site #40
    East Setauket, New York 11733, United States
  • Exelixis Clinical Site #11
    New York, New York 10029, United States
  • Exelixis Clinical Site #37
    The Bronx, New York 10461, United States
  • Exelixis Clinical Site #67
    Cleveland, Ohio 44195, United States
  • Exelixis Clinical Site #49
    Columbus, Ohio 43210, United States
  • Exelixis Clinical Site #64
    Kettering, Ohio 45409, United States
  • Exelixis Clinical Site #71
    Oklahoma City, Oklahoma 73104, United States
  • Exelixis Clinical Site #6
    Oklahoma City, Oklahoma 73120, United States
  • Exelixis Clinical Site #102
    Portland, Oregon 97213, United States
  • Exelixis Clinical Site #45
    Portland, Oregon 97239, United States
  • Exelixis Clinical Site #41
    Bethlehem, Pennsylvania 18015, United States
  • Exelixis Clinical Site #15
    Philadelphia, Pennsylvania 19107, United States
  • Exelixis Clinical Site #55
    Philadelphia, Pennsylvania 19111, United States
  • Exelixis Clinical Site #66
    Pittsburgh, Pennsylvania 15232, United States
  • Exelixis Clinical Site #95
    Charleston, South Carolina 29414, United States
  • Exelixis Clinical Site #13
    Dallas, Texas 75246, United States
  • Exelixis Clinical Site #26
    Dallas, Texas 75390, United States
  • Exelixis Clinical Site #114
    Fort Worth, Texas 76104, United States
  • Exelixis Clinical Site #29
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #39
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #44
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #33
    Lubbock, Texas 79410, United States
  • Exelixis Clinical Site #63
    San Antonio, Texas 78229, United States
  • Exelixis Clinical Site #2
    Salt Lake City, Utah 84112, United States
  • Exelixis Clinical Site #30
    Blacksburg, Virginia 24060, United States
  • Exelixis Clinical Site #14
    Charlottesville, Virginia 22908, United States
  • Exelixis Clinical Site #98
    Albury, New South Wales 2640, Australia
  • Exelixis Clinical Site #101
    Camperdown, New South Wales 2050, Australia
  • Exelixis Clinical Site #115
    Gosford, New South Wales 2250, Australia
  • Exelixis Clinical Site #112
    North Ryde, New South Wales 2109, Australia
  • Exelixis Clinical Site #123
    Randwick, New South Wales 2031, Australia
  • Exelixis Clinical Site #99
    St Albans, Victoria 3021, Australia
  • Exelixis Clinical Site #52
    Ghent, 9000, Belgium
  • Exelixis Clinical Site #54
    Leuven, 3000, Belgium
  • Exelixis Clinical Site #88
    La Roche-sur-Yon, Cedex 9 85925, France
  • Exelixis Clinical Site #8
    Villejuif, Cedex 94805, France
  • Exelixis Clinical Site #92
    Bordeaux, 33076, France
  • Exelixis Clinical Site #93
    Brest, 29229, France
  • Exelixis Clinical Site #87
    Caen, 14076, France
  • Exelixis Clinical Site #69
    Le Mans, 72000, France
  • Exelixis Clinical Site #97
    Lille, 59000, France
  • Exelixis Clinical Site #89
    Lyon, 69373, France
  • Exelixis Clinical Site #109
    Marseille, 13273, France
  • Exelixis Clinical Site #104
    Nice, 06189, France
  • Exelixis Clinical Site #80
    Nîmes, 30029, France
  • Exelixis Clinical Site #78
    Paris, 75005, France
  • Exelixis Clinical Site #7
    Paris, 75010, France
  • Exelixis Clinical Site #68
    Paris, 75013, France
  • Exelixis Clinical Site #72
    Paris, 75015, France
  • Exelixis Clinical Site #82
    Saint-Grégoire, 35760, France
  • Exelixis Clinical Site #119
    Strasbourg, 67000, France
  • Exelixis Clinical Site #107
    Suresnes, 92150, France
  • Exelixis Clinical Site #105
    Vandœuvre-lès-Nancy, 54519, France
  • Exelixis Clinical Site #56
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Exelixis Clinical Site #36
    Tübingen, 72076, Germany
  • Exelixis Clinical Site #84
    Meldola, FC 47014, Italy
  • Exelixis Clinical Site #47
    Rozzano, Milano 20089, Italy
  • Exelixis Clinical Site #108
    Milan, 20132, Italy
  • Exelixis Clinical Site #103
    Milan, 20133, Italy
  • Exelixis Clinical Site #25
    Milan, 20133, Italy
  • Exelixis Clinical Site #4
    Milan, 20133, Italy
  • Exelixis Clinical Site #85
    Naples, 80131, Italy
  • Exelixis Clinical Site #121
    Pavia, 27100, Italy
  • Exelixis Clinical Site #110
    Roma, 00168, Italy
  • Exelixis Clinical Site #12
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Exelixis Clinical Site #74
    Santiago de Compostela, A Coruña 15706, Spain
  • Exelixis Clinical Site #91
    Elche, Alicante 03203, Spain
  • Exelixis Clinical Site #70
    Palma de Mallorca, Balearic Islands 07120 / 07010, Spain
  • Exelixis Clinical Site #113
    Badalona, Barcelona 08916, Spain

Showing the first 100 of 124 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pal SK, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, Suarez C, McGregor BA, Vaishampayan UN, Hauke RJ, Powles T, Van Herpen CML, Courtney KD, Dreicer R, Sudhagoni R, Schwickart M, Andrianova S, Agarwal N. COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. J Clin Oncol. 2025 May 10;43(14):1650-1662. doi: 10.1200/JCO-24-01675. Epub 2025 Feb 18. PubMed 39965176 ↗
  • Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson S. Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine. 2023 Dec 21;67:102376. doi: 10.1016/j.eclinm.2023.102376. eCollection 2024 Jan. PubMed 38204489 ↗
  • Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. PubMed 35690072 ↗
  • Pal SK, McGregor B, Suarez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 7. PubMed 34491815 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Feb 2023, 65 months.

Of 62 industry-sponsored phase 1 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 65 months is above that.

Counting every sponsor, half of 99 studies reached it within 44 months; a quarter within 31 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2017
First posted
May 31, 2017
StartActual
Sep 5, 2017
Primary completionActual
Feb 21, 2023
CompletionEst.
Sep 30, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03170960
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
May 31, 2017
Start date
Sep 5, 2017
Primary completion
Feb 21, 2023
Completion
Sep 30, 2027 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Atezolizumab

Start the discussion